자궁내막증 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The total endometriosis market size in the 7MM was USD 2,300 million in 2023 and is expected to grow significantly over the forecast period owing to launch of new endometriosis therapies.
• Endometriosis is a condition where patches of the endometrium appear in parts of the body other than the womb, such as the fallopian tubes, ovaries, or lungs. During a menstrual cycle, the endometrium thickens and increases its blood supply in preparation for the release of an egg. The body then sheds the endometrium if the egg is not fertilized. Endometrial tissues undergo this process no matter where it is in the body, which can lead to pain, swelling bleeding in those areas.
• Based on the endometrium implants on the tissues outside the uterus, the condition is ranked in one of four stages: Stage 1 or minimal implants, Stage 2 or mild implants, Stage 3 or moderate implants, and Stage 4 or severe implants. Stage 4 is the most widespread, with many deep implants and thick adhesions.

Several factors augment disease propensity at greater risk of developing endometriosis, such as never giving birth, early menarche, late menopause, short menstrual cycles, genetic (mother, aunt or sister) with endometriosis, disorders of the reproductive tract etc.

• An average diagnostic delay of ~6-10 years is seen among patients with endometriosis, mainly due to delays in referral from primary care to a specialist.
• In 2025, the US reported ~7 million prevalent cases of endometriosis, a number expected to grow by 2036, driven by delayed diagnosis, genetic predisposition, hormonal and reproductive factors, environmental exposures, and increasing clinical recognition in specific populations.
• Despite developing novel treatments, the present pharmacological landscape has several drawbacks. Hormone therapy can affect the ability to get pregnant, so it may not be right for everyone. NSAIDs are mostly used as off-label for pain management of endometriosis, but chronic uses may cause kidney damage. Moreover, opioids have high addiction potential.
• Various new therapies are in development with a focus on mentioned limitations of the currently approved drugs. Some of the most prominent ones include HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others.
• Among emerging therapies, OG-6219 is expected to garner the largest market share by 2036.

Endometriosis market growth is expected to be mainly driven by the entry of novel Endometriosis therapies with better clinical profiles, an upsurge in research and development, and an enriched understanding of the disease.

• The rise in Endometriosis market size during the study period (2022-2036) is mainly driven by current Endometriosis treatment options like NSAIDs/opioids and the introduction of Endometriosis pipeline drugs OG-6219, and elagolix + estradiol + norethindrone during the forecast period.

Endometriosis Treatment Market Report Summary

• The Endometriosis therapeutics market report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and Endometriosis treatment market guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current Endometriosis treatment market landscape and result in an overall market shift has been provided in the report.
• The Endometriosis therapeutics market report also encompasses a comprehensive analysis of the Endometriosis market, providing an in-depth examination of its historical and projected market size (2022-36). It also includes the Endometriosis market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The Endometriosis therapeutics market report includes qualitative insights that provide an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM Endometriosis market.

The table given below further depicts the key segments provided in the report:

Key Factors Driving the Growth of the Endometriosis Market

• Rising Endometriosis Prevalence: The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms
• Advancements in Early Diagnostic Techniques for Endometriosis: New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool
• Launch of Emerging Endometriosis Drugs: The dynamics of the endometriosis market are expected to change in the coming years, owing to the launch of emerging therapies such as HMI-115 (Bayer/Hope Medicine), Merigolix/TU2670 (Tiumbio), Linzagolix (Kissei Pharmaceutical), Vipoglanstat (Gesynta Pharma), Estelle (Mithra Pharmaceuticals), VR103 (VaRi Bioscience), and others.

Endometriosis Market

Various key Endometriosis companies are leading the Endometriosis treatment landscape, such as Abbvie, Myovant, Pfizer, ASKA Pharmaceutical, Enteris BioPharma, and others. The details of the country-wise and therapy-wise Endometriosis market size have been provided below.

• In 2023, the total endometriosis market size in the 7MM was ~USD 2,300 million. Among all the available therapies, prescription analgesics (NSAIDs/Opioids) garner the highest market share currently, and is expected to maintain its dominance over the forecast period.
• In the total market size of endometriosis in the 7MM, the United States accounted for the highest market size, i.e., ~USD 1,400 million in 2023.
• In 2023, UK accounted for the highest market share i.e. ~20% in EU4 and the UK region, and Spain accounted for the least market share.
• The growth in market size is mainly driven by the introduction of pipeline candidates OG-6219, and elagolix + estradiol + norethindrone during the forecast period (2026-2036).

Endometriosis Recent Developments

• In December 2025, Hope Medicine reported that its lead pipeline product, HMI-115, received FTD from the US FDA for the treatment of moderate to severe pain associated with endometriosis.
• In October 2025, Hope Medicine announced the successful completion of a global Phase II trial of HMI-115, a potential first-in-class monoclonal antibody. The company plans to initiate Phase III studies to further assess efficacy and safety in women with moderate to severe endometriosis-associated pain.
• In September 2025, Gesynta Pharma AB announced that its clinical trial application for the company's Phase II trial of vipoglanstat for the treatment of endometriosis had been approved by the UK authorities. The clinical trial, named NOVA, intends to evaluate the efficacy and safety of vipoglanstat against placebo in approximately 190 patients with endometriosis across several European countries.
• In March 2025, TiumBio's partner Hansoh Pharma expanded Merigolix (HS-10518) development to include Assisted Reproductive Technology (ART), broadening its therapeutic scope beyond endometriosis.

Endometriosis Drug Chapters

The section dedicated to Endometriosis drugs in the Endometriosis treatment market report provides an in-depth evaluation of late-stage Endometriosis pipeline drugs (Phase III and Phase II) related to Endometriosis.

The drug chapters section provides valuable information on various aspects related to Endometriosis clinical trials, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each Endometriosis drugs. Furthermore, it presents the most recent news updates and press releases on drugs targeting Endometriosis.

Marketed Endometriosis Therapies

ORILISSA (elagolix): AbbVie

ORILISSA (elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist and is available in two oral dosages 150 mg once daily and 200 mg twice daily. ORILISSA inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones estradiol and progesterone. ORILISSA was the first FDA-approved oral treatment for managing moderate-to-severe pain associated with endometriosis.

MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer

MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is an oral once-daily tablet. MYFEMBREE contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries; estradiol (an estrogen) which may reduce the risk of bone loss; and norethindrone acetate (a progestin), which is necessary when women with a uterus (womb) take estrogen. MYFEMBREE was approved as a one-pill, once-a-day therapy for managing moderate-to-severe pain associated with endometriosis in premenopausal women, with the treatment of up to 24 months.

Emerging Endometriosis Therapies

HMI-115: Bayer/Hope Medicine

HMI-115 is a first-in-class monoclonal antibody that targets the prolactin receptor, a key mediator involved in the development and persistence of endometriosis. Prolactin signaling contributes to lesion growth, inflammation, and pain associated with the disease. By blocking the prolactin receptor, HMI-115 aims to alleviate endometriosis-related pain and suppress lesion progression through a non-hormonal mechanism.

Merigolix/TU2670: Tiumbio

TU2670 is an oral, small-molecule GnRH receptor antagonist designed to suppress estradiol production by directly binding to pituitary GnRH receptors. Unlike injectable GnRH agonists, which induce profound hormone suppression to menopausal levels and are associated with reduced patient comfort and adverse effects such as bone loss, TU2670 enables dose-dependent hormonal control limited to therapeutic levels. This targeted suppression is intended to maintain efficacy while reducing hypoestrogenic side effects and improving convenience through oral administration. Currently, a Phase IIa clinical trial is underway in five European countries to evaluate the efficacy and safety of TU2670 in patients with endometriosis-associated pain.

Endometriosis Market Outlook

Without a cure, endometriosis treatments aim to manage symptoms, especially pain and infertility, including drug therapies (analgesic and hormone) and surgery. While drug therapies reduce pain, surgery is currently the only treatment option shown to improve fertility rates. Current treatment guidelines for endometriosis emphasize the management of pain and infertility. Most treatment guidelines recommend using nonsteroidal anti-inflammatory drugs, combined hormonal contraceptives, progestogens (or antiprogestogens), gonadotropin-releasing hormone agonists and antagonists, surgical fulguration or excision of endometrial lesions, or hysterectomy with and without bilateral salpingo-oophorectomy.

Many new molecules with novel mechanisms, like LHRH receptor antagonists, Gonadotropin-releasing hormone stimulants, Prolactin receptor antagonists, among others, are being developed for the treatment of Endometriosis by key Endometriosis companies like ObsEva SA, Myovant Sciences, Hope Medicine, and Organon among others.

In conclusion, despite the lack of appropriate treatment in the current treatment landscape, many potential therapies with novel mechanisms are expected to enter the market, resolving a dire unmet need and leading to significant improvement in the treatment outcome of Endometriosis patients. Hence, with the upcoming availability of new Endometriosis treatment options and increasing healthcare spending across the 7MM, the treatment scenario is expected to experience significant growth during the forecast period (2024-2034).

Endometriosis Understanding and Treatment

Endometriosis is a disease distinguished by endometrial tissue outside the uterine cavity with recurrent intralesional bleeding because of the hormonal responsiveness of ectopic endometrial tissue, resulting in fibrosis. It is a disease of adolescents and reproductive-aged women commonly associated with chronic pelvic pain and infertility. The most common locations for endometriosis are the ovaries, pelvic peritoneum, uterosacral ligaments, and torus uterinus. Atypical pelvic endometriosis localizations can occur in the cervix, vagina, round ligaments, ureter, and nerves. Moreover, rare extrapelvic endometriosis implants can be localized in the upper abdomen, subphrenic fold, or abdominal wall.

Endometriosis Diagnosis

Clinically diagnosing endometriosis can be challenging because the signs and symptoms are nonspecific. A thorough history and a comprehensive assessment of a patient's pain experience are recommended. A stepwise pelvic exam may reveal anatomic features of endometriotic implants, and imaging, predominantly transvaginal ultrasound, can be a useful adjunct.

Laparoscopy- At laparoscopy, endometriosis may be visualized as peritoneal implants, peritoneal windows, endometriomas, and deep infiltrating nodules of endometriosis which may each be associated with adhesions.

Imaging- Imaging has limited utility in diagnosing endometriosis, as it lacks adequate resolution to identify adhesions or superficial peritoneal implants. Ultrasound is cheap and easy to perform but user-dependent; MRI is more accurate but considerably more expensive. As CT of the pelvis does not visualize pelvic organs well, it is not useful in diagnosing endometriosis.

Serum markers- Serum markers for endometriosis have been eagerly sought for their use in diagnosing, measuring disease activity, and monitoring improvement. Serum cytokines, matrix metalloproteinases, adhesion molecules, and markers of angiogenesis or inflammation have been investigated.

Endometrial nerve fibers- Endometrial biopsy is being explored for the diagnosis of endometriosis. Recent studies have shown an increased number of nerve fibers in the endometrium of women with endometriosis compared to women without endometriosis.

Endometriosis Treatment

Current strategies for treating endometriosis include surgical removal of endometriotic lesions by laparoscopy, which reduces pain and improves pregnancy rates, and/or therapeutics that suppress pain, ovarian function, and estrogen action. The recurrence rate of endometriosis is high; estimates show that 21.5% of patients experience recurrence within 2 years after surgery, and 40-50% of patients experience recurrence within 5 years of surgery. Patients with endometriosis thus often undergo several surgeries and/or are treated pharmacologically for decades during their reproductive years.

The available Endometriosis therapies include oral contraceptives (off-label), progestins as the first-line pharmacological treatment, and GnRH agonists/antagonists as the second-line treatment. The latter option leads to hypoestrogenism and is associated with serious side effects, including drug-induced menopause and osteoporosis. Importantly, all these therapies preclude fertility. Persistent pain, a typical and debilitating symptom of endometriosis, is most commonly alleviated with NSAIDs which show variable efficacy and have serious side effects when used for a prolonged time. There is an unmet clinical need for new non-hormonal treatments for endometriosis.

Endometriosis Epidemiology

The Endometriosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent cases, Diagnosed prevalent cases, Age-specific diagnosed prevalent cases, Diagnosed prevalent cases by pain severity, Total treated cases of endometriosis in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2022 to 2036.

• In 2025, the US reported ~7 million prevalent cases of endometriosis, a number expected to grow by 2036, driven by delayed diagnosis, genetic predisposition, hormonal and reproductive factors, environmental exposures, and increasing clinical recognition in specific populations.
• Due to rising awareness and improved, more accurate diagnostic pathways, the diagnosed prevalent cases of endometriosis in the US were approximately 4 million in 2025 and are expected to rise steadily.
• In the US, diagnosed prevalent cases of endometriosis are predominantly managed by gynecologists, accounting for about 3 million cases in 2025 and generalists represent the second-largest prescriber group, managing roughly 500,000 cases in 2025.
• In the United States, diagnosed prevalent cases of endometriosis are stratified across four age groups. The highest concentration of diagnosed cases occurs in the 20-29 years age group with approximately 2 million cases in 2025

KOL Views

To stay abreast of the latest trends in the Endometriosis market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of Endometriosis, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included gynaecologists, medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions such as the Michigan State University College of Human Medicine, Women's Healthcare of Princeton etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Endometriosis market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for Endometriosis, important primary endpoints are verbal rating scale (VRS), numeric rating scale (NRS), endometriosis health profile-30 (EHP-30), endometriosis-associated pelvic pain (EAPP), endometriosis impact questionnaire (EIQ), etc. Based on these parameters, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, a final weightage score is decided, based on which the emerging therapies are ranked.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Endometriosis Report Insights

• Patient Population
• Therapeutic Approaches
• Endometriosis Market Size and Trends
• Existing Market Opportunity

Endometriosis Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage
• Endometriosis Epidemiology Segmentation
• Key Cross Competition
• Endometriosis Report Assessment
• Current Treatment Practices
• Reimbursements
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Unmet needs)

Key Questions:

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in Endometriosis management recommendations?
• Would research and development advances pave the way for future tests and therapies for Endometriosis?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Endometriosis?
• What kind of uptake will the new therapies witness in coming years in Endometriosis patients?

Table of Contents

1 Key Insights

2 Report Introduction

3 Endometriosis Market Overview at a Glance

• 3.1 Market Share (%) Distribution of Endometriosis in 2022
• 3.2 Market Share (%) Distribution of Endometriosis in 2036

4 Executive Summary of Endometriosis

5 Key Events

6 Epidemiology and Market Methodology

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Classification of Endometriosis
  • 7.2.1 American Society for reproductive medicine classification
  • 7.2.2 ENZIAN classification
  • 7.2.3 Endometriosis fertility index
  • 7.2.4 American Association of Gynecological Laparoscopists Classification
• 7.3 Types of Endometriosis
  • 7.3.1 Superficial peritoneal endometriosis
  • 7.3.2 Ovarian endometriosis
  • 7.3.3 Deep infiltrating endometriosis
• 7.4 Etiopathogenesis of Endometriosis
• 7.5 Risk Factors of Endometriosis
• 7.6 Symptoms of Endometriosis
• 7.7 Comorbidities of Endometriosis
  • 7.7.1 Gynecologic comorbidities
  • 7.7.2 Systemic comorbidities
• 7.8 Diagnosis of Endometriosis
  • 7.8.1 Patient and family history
  • 7.8.2 Physical examination
  • 7.8.3 Laparoscopy
  • 7.8.4 Imaging
  • 7.8.5 Serum markers
  • 7.8.6 Endometrial nerve fibers
  • 7.8.7 Diagnostic algorithm of endometriosis
  • 7.8.8 Differential diagnosis of endometriosis
  • 7.8.9 Diagnostic guidelines of endometriosis
• 7.9 Treatment of Endometriosis
  • 7.9.1 Hormonal treatments
  • 7.9.2 Nonhormone treatments
  • 7.9.3 Surgical treatment
  • 7.9.4 Treatment algorithm
  • 7.9.5 Treatment guidelines
• 7.10 Conclusion

8 Epidemiology and Patient Population

• 8.1 Key Findings
• 8.2 Assumptions and Rationale: The 7MM
• 8.3 Epidemiology Scenario in the 7MM
  • 8.3.1 Prevalent cases of endometriosis in the 7MM
  • 8.3.2 Diagnosed prevalent cases of endometriosis in the 7MM
  • 8.3.3 Age-specific diagnosed prevalent cases of endometriosis in the 7MM
  • 8.3.4 Diagnosed prevalent cases of endometriosis by pain severity in the 7MM
  • 8.3.5 Total treated cases of endometriosis in the 7MM
• 8.4 Epidemiology Scenario in the US
  • 8.4.1 Prevalent cases of endometriosis in the US
  • 8.4.2 Diagnosed prevalent cases of endometriosis in the US
  • 8.4.3 Age-specific diagnosed prevalent cases of endometriosis in the US
  • 8.4.4 Diagnosed prevalent cases of endometriosis by pain severity in the US
  • 8.4.5 Total treated cases of endometriosis in the US
• 8.5 Epidemiology Scenario in EU4 and the UK
  • 8.5.1 Prevalent cases of endometriosis in EU4 and the UK
  • 8.5.2 Diagnosed prevalent cases of endometriosis in EU4 and the UK
  • 8.5.3 Age-specific diagnosed prevalent cases of endometriosis in EU4 and the UK
  • 8.5.4 Diagnosed prevalent cases of endometriosis by pain severity in EU4 and the UK
  • 8.5.5 Total treated cases of endometriosis in EU4 and the UK
• 8.6 Epidemiology Scenario in Japan
  • 8.6.1 Prevalent cases of endometriosis in Japan
  • 8.6.2 Diagnosed prevalent cases of endometriosis in Japan
  • 8.6.3 Age-specific diagnosed prevalent cases of endometriosis in Japan
  • 8.6.4 Diagnosed prevalent cases of endometriosis by pain severity in Japan
  • 8.6.5 Total treated cases of endometriosis in Japan

9 Patient Journey

10 Marketed Therapies

• 10.1 Key Cross of Marketed Therapies
• 10.2 ORILISSA (elagolix): AbbVie
  • 10.2.1 Product description
  • 10.2.2 Regulatory milestones
  • 10.2.3 Other developmental activities
  • 10.2.4 Pivotal clinical trial
  • 10.2.5 Ongoing pipeline activity
• 10.3 MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer
  • 10.3.1 Product description
  • 10.3.2 Regulatory milestones
  • 10.3.3 Other developmental activities
  • 10.3.4 Pivotal clinical trial
  • 10.3.5 Ongoing pipeline activity
• 10.4 RELUMINA (relugolix): ASKA Pharmaceutical
  • 10.4.1 Product description
  • 10.4.2 Regulatory milestones
  • 10.4.3 Other developmental activities
  • 10.4.4 Pivotal clinical trial

11 Emerging Therapies

• 11.1 Key Cross Competition
• 11.2 ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
  • 11.2.1 Product description
  • 11.2.2 Clinical developmental activities
• 11.3 Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
  • 11.3.1 Product description
  • 11.3.2 Other developmental activities
  • 11.3.3 Clinical developmental activities
  • 11.3.4 Safety and efficacy
• 11.4 OVAREST (leuprorelin oral): SWK/Enteris BioPharma
  • 11.4.1 Product Description
  • 11.4.2 Other developmental activities
  • 11.4.3 Clinical developmental activities
  • 11.4.4 Safety and efficacy
• 11.5 HMI-115: Bayer/Hope Medicine
  • 11.5.1 Product description
  • 11.5.2 Other developmental activities
  • 11.5.3 Clinical developmental activities
• 11.6 TU2670 (NCE-403): Tiumbio
  • 11.6.1 Product description
  • 11.6.2 Clinical developmental activities
  • 11.6.3 Safety and efficacy
• 11.7 OG-6219: Organon
  • 11.7.1 Product description
  • 11.7.2 Other developmental activities
  • 11.7.3 Clinical developmental activities
  • 11.7.4 Safety and efficacy

12 Endometriosis: 7 Major Market Analysis

• 12.1 Key Findings
• 12.2 Market Outlook
• 12.3 Key Market Forecast Assumptions
• 12.4 Market Size in the 7MM
  • 12.4.1 Total market size of endometriosis in the 7MM
  • 12.4.2 Market size of endometriosis by therapies in the 7MM
• 12.5 The United States Market Size
  • 12.5.1 Total market size of endometriosis in the US
  • 12.5.2 Market size of endometriosis by therapies in the US
• 12.6 EU4 and the UK Market Size
  • 12.6.1 Total market size of endometriosis in EU4 and the UK
  • 12.6.2 Market size of endometriosis by therapies in EU4 and the UK
• 12.7 Japan Market Size
  • 12.7.1 Total market size of endometriosis in Japan
  • 12.7.2 Market size of endometriosis by therapies in Japan

13 Market Access and Reimbursement

• 13.1 Key HTA Decisions for Endometriosis
• 13.2 Patient Access Programs

14 SWOT Analysis

15 Unmet needs

16 Appendix

• 16.1 Bibliography
• 16.2 Acronyms and Abbreviations
• 16.3 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight